https://www.selleckchem.com/pr....oducts/ar-c155858.ht
1% (10/124) of patients. All ACVR2A mutations were accompanied by MSI. The 5-year overall survival rates of ACVR2A wild-type patients and ACVR2A-mutated patients were 57% and 90%, respectively (P = 0.048). Multivariate analysis revealed that older age (P = 0.015), distant metastasis (P 0.001), and ACVR2A wild-type status (P = 0.04 were independent prognostic factors for overall survival. Our study demonstrated that gastric cancer patients with ACVR2A mutation have a significantly better prognosis than those without. Dysfunctio
Like
Comment
Share
